Loading...

Oasmia Pharmaceutical

DB:OMAX
Snowflake Description

Exceptional growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
OMAX
DB
SEK2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Oasmia Pharmaceutical AB (publ) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. The last earnings update was 19 days ago. More info.


Add to Portfolio Compare Print
OMAX Share Price and Events
7 Day Returns
0%
DB:OMAX
-1.1%
DE Biotechs
-0.3%
DE Market
1 Year Returns
-
DB:OMAX
-9.6%
DE Biotechs
-19.1%
DE Market
OMAX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Oasmia Pharmaceutical (OMAX) 0% 0% - - -27.6% -61.1%
DE Biotechs -1.1% 1% -14.2% -9.6% 28.9% -5%
DE Market -0.3% -4.9% -12.1% -19.1% -3.9% 2.6%
1 Year Return vs Industry and Market
  • No trading data on OMAX.
  • No trading data on OMAX.
Price Volatility
OMAX
Industry
5yr Volatility vs Market

OMAX Value

 Is Oasmia Pharmaceutical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Oasmia Pharmaceutical to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Oasmia Pharmaceutical.

DB:OMAX Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:OMAX
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 9.5%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 0.86
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.856 (1 + (1- 22%) (5.88%))
0.896
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.9
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.54% + (0.896 * 9.46%)
9.01%

Discounted Cash Flow Calculation for DB:OMAX using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Oasmia Pharmaceutical is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:OMAX DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (SEK, Millions) -79.00 34.00 176.00 146.08 122.71
Source Analyst x1 Analyst x1 Analyst x1 Est @ -17%, capped from -25.07% Est @ -16%, capped from -25.07%
Present Value
Discounted (@ 9.01%)
-72.47 28.61 135.86 103.44 79.70
Present value of next 5 years cash flows SEK275.14
DB:OMAX DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= SEK122.71 × (1 + 0.54%) ÷ (9.01% – 0.54%)
SEK1,456.38
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= SEK1,456.38 ÷ (1 + 9.01%)5
SEK945.98
DB:OMAX Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= SEK275.14 + SEK945.98
SEK1,221.11
Equity Value per Share
(SEK)
= Total value / Shares Outstanding
= SEK1,221.11 / 200.24
SEK0.49
DB:OMAX Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:OMAX represents 0.08075x of OM:OASM
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.08075x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (SEK) x Listing Adjustment Factor
= SEK 6.10 x 0.08075
€0.49
Value per share (EUR) From above. €0.49
Current discount Discount to share price of €0.81
= -1 x (€0.81 - €0.49) / €0.49
-65.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Oasmia Pharmaceutical is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Oasmia Pharmaceutical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Oasmia Pharmaceutical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:OMAX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-10-31) in SEK SEK-0.86
OM:OASM Share Price ** OM (2018-09-21) in SEK SEK10.08
Europe Biotechs Industry PE Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 25.12x
Germany Market PE Ratio Median Figure of 418 Publicly-Listed Companies 16.62x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Oasmia Pharmaceutical.

DB:OMAX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:OASM Share Price ÷ EPS (both in SEK)

= 10.08 ÷ -0.86

-11.75x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Oasmia Pharmaceutical is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Oasmia Pharmaceutical is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Oasmia Pharmaceutical's expected growth come at a high price?
Raw Data
DB:OMAX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -11.75x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
116.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 0.98x
Germany Market PEG Ratio Median Figure of 279 Publicly-Listed Companies 1.33x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Oasmia Pharmaceutical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Oasmia Pharmaceutical's assets?
Raw Data
DB:OMAX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-10-31) in SEK SEK1.80
OM:OASM Share Price * OM (2018-09-21) in SEK SEK10.08
Germany Biotechs Industry PB Ratio Median Figure of 13 Publicly-Listed Biotechs Companies 2.37x
Germany Market PB Ratio Median Figure of 567 Publicly-Listed Companies 1.72x
DB:OMAX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:OASM Share Price ÷ Book Value per Share (both in SEK)

= 10.08 ÷ 1.80

5.59x

* Primary Listing of Oasmia Pharmaceutical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Oasmia Pharmaceutical is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Oasmia Pharmaceutical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Oasmia Pharmaceutical has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

OMAX Future Performance

 How is Oasmia Pharmaceutical expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
116.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Oasmia Pharmaceutical expected to grow at an attractive rate?
  • Oasmia Pharmaceutical's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • Oasmia Pharmaceutical's earnings growth is expected to exceed the Germany market average.
  • Oasmia Pharmaceutical's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:OMAX Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:OMAX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 116.1%
DB:OMAX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 108.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 16.9%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24.3%
Germany Market Earnings Growth Rate Market Cap Weighted Average 10.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:OMAX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:OMAX Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-04-30 1,046 213 343 1
2020-04-30 461 71 87 1
2019-04-30 48 -43 -119 1
DB:OMAX Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2018-10-31 13 -97 -153
2018-07-31 13 -103 -117
2018-04-30 12 -124 -118
2018-01-31 10 -124 -128
2017-10-31 10 -144 -139
2017-07-31 8 -134 -155
2017-04-30 7 -133 -160
2017-01-31 7 -145 -151
2016-10-31 16 -147 -137
2016-07-31 19 -142 -139
2016-04-30 23 -128 -142
2016-01-31 26 -112 -139

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Oasmia Pharmaceutical's earnings are expected to grow significantly at over 20% yearly.
  • Oasmia Pharmaceutical's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:OMAX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Oasmia Pharmaceutical Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:OMAX Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-04-30 1.55 1.55 1.55 1.00
2020-04-30 0.39 0.39 0.39 1.00
2019-04-30 -0.54 -0.54 -0.54 1.00
DB:OMAX Past Financials Data
Date (Data in SEK Millions) EPS *
2018-10-31 -0.86
2018-07-31 -0.67
2018-04-30 -0.71
2018-01-31 -0.85
2017-10-31 -1.02
2017-07-31 -1.29
2017-04-30 -1.42
2017-01-31 -1.36
2016-10-31 -1.27
2016-07-31 -1.33
2016-04-30 -1.39
2016-01-31 -1.39

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Oasmia Pharmaceutical is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).
X
Future performance checks
We assess Oasmia Pharmaceutical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Oasmia Pharmaceutical has a total score of 6/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

OMAX Past Performance

  How has Oasmia Pharmaceutical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Oasmia Pharmaceutical's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Oasmia Pharmaceutical does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Oasmia Pharmaceutical's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Oasmia Pharmaceutical's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Oasmia Pharmaceutical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Oasmia Pharmaceutical Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:OMAX Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-10-31 13.05 -153.28 106.01
2018-07-31 12.68 -117.39 106.11
2018-04-30 12.33 -118.01 108.61
2018-01-31 10.48 -127.97 114.51
2017-10-31 9.58 -138.78 125.72
2017-07-31 7.70 -155.04 135.19
2017-04-30 7.20 -160.24 139.20
2017-01-31 7.35 -151.14 139.12
2016-10-31 16.14 -136.59 140.95
2016-07-31 19.06 -138.64 148.17
2016-04-30 23.10 -141.54 155.77
2016-01-31 25.86 -138.64 149.77
2015-10-31 17.99 -141.01 136.00
2015-07-31 19.28 -124.33 121.75
2015-04-30 19.02 -117.50 111.27
2015-01-31 23.05 -125.21 122.59
2014-10-31 25.70 -127.93 128.94
2014-07-31 27.94 -119.88 124.41
2014-04-30 29.73 -105.11 120.29
2014-01-31 29.92 -90.27 108.69
2013-10-31 34.75 -75.38 102.34
2013-07-31 43.92 -71.28 106.22
2013-04-30 46.43 -72.38 105.02
2013-01-31 52.25 -69.17 107.51
2012-10-31 56.11 -70.86 110.85
2012-07-31 53.10 -69.73 108.20
2012-04-30 64.28 -65.67 114.63
2012-01-31 70.25 -67.45 118.54

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Oasmia Pharmaceutical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Oasmia Pharmaceutical has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Oasmia Pharmaceutical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Oasmia Pharmaceutical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Oasmia Pharmaceutical has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

OMAX Health

 How is Oasmia Pharmaceutical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Oasmia Pharmaceutical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Oasmia Pharmaceutical's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Oasmia Pharmaceutical's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Oasmia Pharmaceutical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Oasmia Pharmaceutical Company Filings, last reported 1 month ago.

DB:OMAX Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-10-31 400.94 123.39 4.61
2018-07-31 321.80 168.45 0.58
2018-04-30 345.04 187.26 15.58
2018-01-31 363.83 161.27 47.66
2017-10-31 392.43 138.19 68.79
2017-07-31 406.01 160.81 128.41
2017-04-30 300.37 168.73 28.00
2017-01-31 303.23 164.85 23.26
2016-10-31 302.02 163.52 32.01
2016-07-31 289.58 176.83 23.02
2016-04-30 326.05 139.94 26.21
2016-01-31 342.51 114.43 27.20
2015-10-31 360.82 113.19 71.60
2015-07-31 335.91 107.00 25.56
2015-04-30 375.71 107.00 48.99
2015-01-31 405.79 107.00 77.56
2014-10-31 269.04 145.00 27.14
2014-07-31 295.75 145.00 58.09
2014-04-30 281.91 145.00 48.24
2014-01-31 251.83 145.00 18.37
2013-10-31 282.27 105.00 10.85
2013-07-31 300.93 105.00 38.83
2013-04-30 319.15 105.00 62.96
2013-01-31 342.14 105.00 92.34
2012-10-31 239.59 109.65 2.02
2012-07-31 254.15 90.00 13.36
2012-04-30 273.47 32.80 2.03
2012-01-31 293.21 0.00 4.93
  • Oasmia Pharmaceutical's level of debt (30.8%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (37.4% vs 30.8% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Oasmia Pharmaceutical has less than a year of cash runway based on current free cash flow.
  • Oasmia Pharmaceutical has less than a year of cash runway if free cash flow continues to grow at historical rates of 17.7% each year.
X
Financial health checks
We assess Oasmia Pharmaceutical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Oasmia Pharmaceutical has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

OMAX Dividends

 What is Oasmia Pharmaceutical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Oasmia Pharmaceutical dividends.
If you bought €2,000 of Oasmia Pharmaceutical shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Oasmia Pharmaceutical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Oasmia Pharmaceutical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:OMAX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 328 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 1%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:OMAX Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2021-04-30
2020-04-30
2019-04-30

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Oasmia Pharmaceutical has not reported any payouts.
  • Unable to verify if Oasmia Pharmaceutical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Oasmia Pharmaceutical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Oasmia Pharmaceutical has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Oasmia Pharmaceutical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Oasmia Pharmaceutical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Oasmia Pharmaceutical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

OMAX Management

 What is the CEO of Oasmia Pharmaceutical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mikael Asp
COMPENSATION SEK2,226,000
AGE 56
TENURE AS CEO 3.6 years
CEO Bio

Mr. Mikael Asp has been the Chief Executive Officer of Oasmia Pharmaceutical AB (publ) May 28, 2015 and has been its Head of Quality Assurance since 2013. Mr. Asp has 25 years of experience from several companies within international pharmaceutical industry in research and development, production, quality assurance and as Qualified Person (QP). Mr. Asp holds a Master of Science degree in Chemical Engineering from Royal Institute of Technology, Stockholm.

CEO Compensation
  • Mikael's compensation has increased whilst company is loss making.
  • Mikael's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Oasmia Pharmaceutical management team in years:

3.6
Average Tenure
56
Average Age
  • The tenure for the Oasmia Pharmaceutical management team is about average.
Management Team

Julian Aleksov

TITLE
Co-Founder & Executive Chairman
COMPENSATION
SEK3M
AGE
53
TENURE
19.9 yrs

Mikael Asp

TITLE
CEO & Head of Quality Assurance
COMPENSATION
SEK2M
AGE
56
TENURE
3.6 yrs

Anders Blom

TITLE
CFO & Executive VP
AGE
49
TENURE
1.2 yrs

Och Ljungmark

TITLE
Head of Accounting and Human Resources
AGE
68
TENURE
13.9 yrs

John Cosby

TITLE
Head of Regulatory Affairs
AGE
56
TENURE
12.9 yrs

Dzianis Babrou

TITLE
Head of Product Development

Henrik Rönnberg

TITLE
Chief Medical Officer of Animal Health
TENURE
3.3 yrs

Nina Heldring

TITLE
Head of Clinical Development

Jarl Jungnelius

TITLE
Senior Medical Advisor
TENURE
2.8 yrs
Board of Directors Tenure

Average tenure and age of the Oasmia Pharmaceutical board of directors in years:

3.6
Average Tenure
53
Average Age
  • The tenure for the Oasmia Pharmaceutical board of directors is about average.
Board of Directors

Julian Aleksov

TITLE
Co-Founder & Executive Chairman
COMPENSATION
SEK3M
AGE
53
TENURE
3.6 yrs

Bo Cederstrand

TITLE
Director
COMPENSATION
SEK175K
AGE
79
TENURE
18.9 yrs

Lars Bergkvist

TITLE
Director
COMPENSATION
SEK197K
AGE
54
TENURE
3.6 yrs

Alexander Kotsinas

TITLE
Director
COMPENSATION
SEK197K
AGE
51
TENURE
5.3 yrs

Per Langö

TITLE
Director
COMPENSATION
SEK115K
AGE
49
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • Oasmia Pharmaceutical insiders have sold more shares than they have bought in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
28. Sep 18 Sell Julian Aleksov Individual 25. Sep 18 25. Sep 18 -36,751 €1.16 €-42,594
28. Sep 18 Buy Julian Aleksov Individual 27. Sep 18 27. Sep 18 9,500 €1.40 €13,286
14. Sep 18 Buy Anders Blom Individual 14. Sep 18 14. Sep 18 10,000 €0.74 €7,354
07. Sep 18 Buy Anders Blom Individual 07. Sep 18 07. Sep 18 25,000 €0.66 €16,472
06. Sep 18 Buy Julian Aleksov Individual 06. Sep 18 06. Sep 18 36,751 €0.64 €23,601
30. Jan 18 Buy Anders Blom Individual 29. Jan 18 29. Jan 18 15,000 €0.43 €6,435
29. Jan 18 Buy Anders Blom Individual 25. Jan 18 26. Jan 18 40,000 €0.37 €13,959
29. Dec 17 Sell Alceco International S.A. Company 27. Dec 17 27. Dec 17 -2,230,964 €0.25 €-568,627
X
Management checks
We assess Oasmia Pharmaceutical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Oasmia Pharmaceutical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

OMAX News

External News
Loading...
Simply Wall St News

OMAX Company Info

Map
Description

Oasmia Pharmaceutical AB (publ) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations and drug-delivery systems based on cytostatics. The company’s approved products include Paclical/Apealea, a water-soluble formulation of XR17 and paclitaxel to treat cancers, such as lung, breast, and ovarian cancer; and Paccal Vet, a formulation for the treatment of squamous cell carcinoma and mammary carcinoma in dogs. It develops Doxophos, a formulation of XR17 and doxorubicin to treat cancer comprising leukaemia, breast cancer, and lymphoma; Docecal, a formulation of XR17 and docetaxel for the treatment of prostate, lung, and breast cancer; OAS-19, a cancer drug; and KB9520 to treat various types of cancer. The company also develops Doxophos Vet, a formulation to treat lymphoma in dogs. Oasmia Pharmaceutical AB (publ) was founded in 1990 and is based in Uppsala, Sweden.

Details
Name: Oasmia Pharmaceutical AB (publ)
OMAX
Exchange: DB
Founded: 1990
SEK202,705,003
200,237,827
Website: http://www.oasmia.com
Address: Oasmia Pharmaceutical AB (publ)
Vallongatan 1,
Uppsala,
752 28,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM OASM Class A Shares OMX Nordic Exchange Stockholm SE SEK 30. Dec 2005
DB OMAX Class A Shares Deutsche Boerse AG DE EUR 30. Dec 2005
LSE 0N4A Class A Shares London Stock Exchange GB SEK 30. Dec 2005
BATS-CHIXE OASMS Class A Shares BATS 'Chi-X Europe' GB SEK 30. Dec 2005
NasdaqCM OASM ADR Nasdaq Capital Market US USD 26. Oct 2015
Number of employees
Current staff
Staff numbers
57
Oasmia Pharmaceutical employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/12/19 21:58
End of day share price update: 2018/09/21 00:00
Last estimates confirmation: 2018/12/13
Last earnings filing: 2018/11/30
Last earnings reported: 2018/10/31
Last annual earnings reported: 2018/04/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.